Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies

DISEASE CHARACTERISTICS:

Diagnosis of 1 of the following:

Myelodysplastic syndromes (MDS)

International Prognostic Scoring System (IPSS) score ≥ intermediate-2
Chronic myelomonocytic leukemia
Acute myeloid leukemia arising from MDS

Must have failed or are ineligible for or intolerant to treatment with azacitidine

Patients with normal marrow cytogenetics or an isolated 5q- abnormality must have failed or are ineligible for or intolerant to treatment with lenalidomide
Patients who are HLA-DR15-positive must have failed or are ineligible for pharmacologic immunosuppression (e.g., anti-thymocyte globulin, cyclosporine, steroids)
No presence of cytotoxic antibodies against donor lymphocytes
No HLA-identical donor available OR ineligible for HLA-identical allogeneic bone marrow transplantation

HLA partially mismatched (haploidentical) related donor available

First-degree related donor, including half-siblings or first cousins
Inherited recombinant haplotype from parents allowed if donor shares ≥ 1 HLA antigen at each of the HLA-A, -B, and DR loci

PATIENT CHARACTERISTICS:

ECOG performance status (PS) 0-1 OR Karnofsky PS 80-100%
Bilirubin < 3.0 mg/dL
AST and ALT ≤ 4 times upper limit of normal
Creatinine < 3.0 mg/dL
LVEF > 35%

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
Recovered from prior therapy
No prior transfusions from donor
At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy
No other concurrent investigational drugs